SKYLINK™
Tumor-selective linker technology for the next generation of ADCs.

SKYLINK™ is a proprietary linker platform designed to improve the therapeutic index of ADCs through controlled, tumor-selective payload release. By minimizing systemic payload exposure while maximizing intratumoral drug delivery, SKYLINK™ aims to:
• Reduce dose-limiting hematological toxicity.
• Improve efficacy in treatment-resistant tumors.
• Expand the therapeutic window across multiple ADC modalities.
• Enable next-generation and dual-payload ADCs.

Target Discovery Platform

Expanding the landscape of actionable targets for next-generation ADCs.

While most ADC programs focus on a limited number of well-established tumor antigens, many highly relevant cell surface proteins remain underexplored. Skymab has developed an integrated target discovery platform combining bioinformatics, tumor biology, single-cell analyses, and translational validation to identify differentiated targets with the highest therapeutic potential.

Our proprietary workflow prioritizes targets based on multiple criteria, including:

• Tumor-selective expression and limited expression in healthy tissues.
• Association with aggressive disease, treatment resistance, or poor clinical outcomes.
• Expression across molecular subtypes and underserved patient populations.
• Compatibility with ADC mechanisms of action and combination therapies.
• Robust validation using patient samples, translational datasets, and preclinical models.

This approach enables the discovery of novel ADC opportunities beyond conventional target classes while identifying the patients most likely to benefit from targeted therapies.